Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis

Table 1

Pretreatment and treatment characteristics for all and PSM patients per SIRI status.

Covariate	All patients (N = 876)	SIRI ≥ 1.9 (N = 487)	SIRI < 1.9 (N = 389)	value	PSM patients (N = 608)	SIRI ≥ 1.9 (N = 304)	SIRI < 1.9 (N = 304)	value
Median age, y (range)	64 (29–79)	65 (31–79)	63 (29–79)	0.56	65 (31–79)	64 (31–79)	65 (34–79	0.87
Age group, y (%)
≤70 years	772 (88.1)	428 (86.7)	344 (88.4)	0.64	542 (89.1)	270 (88.8)	272 (89.5)	0.82
>70 years	104 (11.9)	59(13.3)	45 (11.6)		66 (10.9)	34 (11.2)	32 (10.5)
Gender, n (%)
Male	539 (61.5)	291 (59.8)	248 (63.8)	0.32	368 (60.5)	180 (59.2)	188 (61.8)	0.49
Female	337 (38.5)	196 (40.2)	141 (36.2)		240 (39.5)	124 (40.8)	116 (38.2)
KPS, n (%)
90–100	751 (71.7)	269 (71.0)	482 (72.0)	0.64	442 (72.7)	219 (72.0)	223 (73.4)	0.79
70–80	297 (28.3)	110 (29.0)	187 (28.0)		166 (27.3)	85 (28.0)	81 (26.6)
Histology, n (%)
AC	567 (54.1)	212 (55.9)	355 (53.1)	0.39	326 (53.6)	157 (51.6)	169 (55.6)	0.32
SCC	481 (45.9)	167 (44.1)	314 (46.9)		282 (46.4)	147 (48.4)	135 (44.4)
T-stage, n (%)
1–2	361 (34.4)	116 (30.6)	245 (36.6)	0.28	254 (41.8)	130 (42.8)	124 (40.8)	0.55
3–4	687 (65.6)	263 (69.4)	424 (63.4)		354 58.2)	174 (57.2)	180 (59.2)
N-stage, n (%)
2	531 (50.7)	195 (51.5)	336 (50.2)	0.55	317 (52.1)	161 (53.0)	156 (51.3)	0.76
3	517 (49.3)	184 (48.5)	333 (49.8)		291 (47.9)	143 (47.0)	148 (48.7)
Tumor stage, n (%)
IIIB	617 (58.9)	217 (57.3)	400 (59.8)	0.67	369 (60.7)	188 (61.8)	181 (59.5)	064
IIIC	431 (41.1)	162 (42.7)	269 (40.2)		239 (39.3)	116 (38.2)	123 (40.5)

Abbreviations. SIRI: systemic inflammation response index; PSM: propensity score matching; KPS: Karnofsky performance score; AC: adenocarcinoma; SCC: squamous cell carcinoma; T: tumor; N: node.